Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chulalongkorn University
With
Thanyarak Institute
National Research Council of Thailand
Eighty individuals with MAP will be randomly assigned into two treatment groups, i.e. treatment with quetiapine and haloperidol. The quetiapine group will receive quetiapine at least 100 mg per day and the haloperidol group will receive haloperidol at least 2 mg per day orally once a day for four weeks. The doses will be increased every 5 days until no psychotic symptom is observed from the Positive and Negative Syndrome Scale. Common antipsychotic adverse events will be checked and documented daily.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Having a psychotic episode with current use of methamphetamine
Positive urine toxicology test for methamphetamine on the first day of hospitalization
You may not be if
Using other illegal substances
Having a history of primary psychotic disorders or using antipsychotic agents
Having a chronic medical disease, e.g. essential hypertension, diabetes, epilepsy, stroke
